Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

What You Need to Know About COVID-19 & Therapies for Rheumatic Diseases

Jason Liebowitz, MD, FACR  |  December 6, 2022

PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided…

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2022COVID-19

Clinical Rheumatology Year in Review—2022

Samantha C. Shapiro, MD  |  December 4, 2022

In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022COVID-19pegloticaseprednisolone

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Walter P. Maksymowych, MB ChB, FACP, FRCP(C)  |  December 1, 2022

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2022ACR Convergence 2022 – PsAPsoriatic Arthritis

New Findings for Polymyalgia Rheumatica & Osteoarthritis

Ruth Jessen Hickman, MD  |  December 1, 2022

The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2022OsteoarthritisPolymyalgia Rheumaticasarilumabweight loss

Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022

Ruth Jessen Hickman, MD  |  November 28, 2022

PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…

Filed under:ACR ConvergenceConditionsMeeting ReportsSjögren’s DiseaseSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022DörnerLupusSjogren'sSLEsystemic lupus erythematous

Ethics Forum: Has the Patient Asked for More Than Can Be Ethically Allowed?

Richard L. Allman, MD, MS, FACP, FACR  |  November 10, 2022

The patient, a 76-year-old woman, had very active polyarticular rheumatoid arthritis (RA), despite triple therapy with conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), low-dose corticosteroids and occasional intra-articular injections—the latter providing only transient symptomatic relief. She had elevated inflammatory markers and a 28-joint Disease Activity Score (DAS-28) score of 7.4.  Because of the severity of her…

Filed under:EthicsProfessional Topics Tagged with:Ethics ForumPrescription drugs

Case Report: Lupus Nephritis or a Mimic?

Matthew J. Mandell, DO, Yishui Chen, MD, Prerna Rastogi, MD, PhD, & Rebecca Tuetken, MD, PhD  |  November 10, 2022

Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involve­ment. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis.  We present…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportFellowsFellows ForumFellows-in-TrainingLupus nephritisparvovirus B19syphilis

A Primer on Imaging in Myositis

Rochelle Castillo, MD, MS, Andro Licaros, MD, & Jemima Albayda, MD  |  November 9, 2022

In medicine, as in advertising, pictures can be worth a thousand words. From arthritis to vasculitis, imaging studies have been variably employed to aid in the diagnosis, treatment, risk stratification and prognostication of patients with rheumatic and musculoskeletal disorders. The same holds true with the idiopathic inflammatory myopathies (IIM), in which the clinical utility is…

Filed under:ConditionsMyositis Tagged with:dermatomyositisMagnetic resonance imaging (MRI)myositispositron emission tomography (PET)Ultrasound

The 2022 ARP President’s & Merit Awards

Patrice Fusillo  |  November 6, 2022

During ACR Convergence 2022 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…

Filed under:AwardsProfessional TopicsResearch Rheum Tagged with:Adena BattermanBrit DonaldsonClinical researchDr. Aileen DavisDr. Charles G. HelmickDr. Jan K. RichardsonDr. Janet L. PooleDr. Kaleb MichaudDr. Linda LiHannah PetersonHeather BenhamMarian T. HannanSue MacQueenThomas Bye

Speak Out Rheum: Racism’s Impact on Patient-Provider Relationships

Mia Taylor Chandler, MD, MPH  |  November 6, 2022

“I tell everyone who comes into her room now, ‘You will not disrespect my daughter again. No one will,’” recounts Sarah’s mother. “Every time a [provider] acts rude to her, Sarah tells me, ‘Ma, I’m used to it now,’ and I have to insist ‘No! Baby, you should never get used to that.’ … Dr….

Filed under:OpinionProfessional TopicsSpeak Out Rheum Tagged with:biasDisparitiesRacismSpeak Out Rheumatology

  • « Previous Page
  • 1
  • …
  • 72
  • 73
  • 74
  • 75
  • 76
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences